EP4493541A4 - C4-carbonsäure-substituierte tryptaminderivate und verfahren zu ihrer verwendung - Google Patents

C4-carbonsäure-substituierte tryptaminderivate und verfahren zu ihrer verwendung

Info

Publication number
EP4493541A4
EP4493541A4 EP22931274.9A EP22931274A EP4493541A4 EP 4493541 A4 EP4493541 A4 EP 4493541A4 EP 22931274 A EP22931274 A EP 22931274A EP 4493541 A4 EP4493541 A4 EP 4493541A4
Authority
EP
European Patent Office
Prior art keywords
triptamine
carbohydrate
derivatives
substituted
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22931274.9A
Other languages
English (en)
French (fr)
Other versions
EP4493541A1 (de
Inventor
Jillian M Hagel
Ye Cai
Kaveh Matinkhoo
David James Press
Glynnis Elizabeth Jensen
Peter J Facchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enveric Biosciences Canada Inc
Original Assignee
Enveric Biosciences Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enveric Biosciences Canada Inc filed Critical Enveric Biosciences Canada Inc
Priority claimed from PCT/CA2022/051228 external-priority patent/WO2023173196A1/en
Publication of EP4493541A1 publication Critical patent/EP4493541A1/de
Publication of EP4493541A4 publication Critical patent/EP4493541A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22931274.9A 2022-03-18 2022-08-11 C4-carbonsäure-substituierte tryptaminderivate und verfahren zu ihrer verwendung Pending EP4493541A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263321440P 2022-03-18 2022-03-18
US202263347835P 2022-06-01 2022-06-01
PCT/CA2022/051228 WO2023173196A1 (en) 2022-03-18 2022-08-11 C4-carboxylic acid-substituted tryptamine derivatives and methods of using

Publications (2)

Publication Number Publication Date
EP4493541A1 EP4493541A1 (de) 2025-01-22
EP4493541A4 true EP4493541A4 (de) 2026-02-25

Family

ID=93294637

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22931274.9A Pending EP4493541A4 (de) 2022-03-18 2022-08-11 C4-carbonsäure-substituierte tryptaminderivate und verfahren zu ihrer verwendung

Country Status (4)

Country Link
US (1) US20250197351A1 (de)
EP (1) EP4493541A4 (de)
AU (1) AU2022446955A1 (de)
CA (1) CA3246245A1 (de)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4174016B2 (ja) * 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
WO2010059711A1 (en) * 2008-11-18 2010-05-27 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US20210403425A1 (en) * 2020-06-30 2021-12-30 Field Trip Psychedelics Inc. Tryptamine prodrugs
WO2022125616A1 (en) * 2020-12-09 2022-06-16 Caamtech, Inc. Dialkyl trytamines and their therapeutic uses
WO2022236407A1 (en) * 2021-05-10 2022-11-17 London Pharmaceuticals And Research Corporation Psilocybin and psilocin conjugates for treatment of mental illnesses
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4174016B2 (ja) * 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
WO2010059711A1 (en) * 2008-11-18 2010-05-27 Wisconsin Alumni Research Foundation Sigma-1 receptor ligands and methods of use
US20210403425A1 (en) * 2020-06-30 2021-12-30 Field Trip Psychedelics Inc. Tryptamine prodrugs
WO2022125616A1 (en) * 2020-12-09 2022-06-16 Caamtech, Inc. Dialkyl trytamines and their therapeutic uses
WO2022236407A1 (en) * 2021-05-10 2022-11-17 London Pharmaceuticals And Research Corporation Psilocybin and psilocin conjugates for treatment of mental illnesses
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] Chemical Abstract Service, Columbus, Ohio, US; 17 August 2006 (2006-08-17), XP093353635, retrieved from https://stn.org/stn/# Database accession no. 902412-24-2 *
FERRIZ J.M. ET AL: "Prodrug Design of Phenolic Drugs", CURRENT PHARMACEUTICAL DESIGN, vol. 16, no. 18, 1 June 2010 (2010-06-01), NL, pages 2033 - 2052, XP055834786, ISSN: 1381-6128, DOI: 10.2174/138161210791293042 *
JULIA MARC ET AL: "Indoles. XXII. New synthesis of the indole nucleus. Application to psilocine", CHIMICA THERAPEUTICA, vol. 5, no. 4, 1 January 1970 (1970-01-01), pages 279 - 284, XP093353528, ISSN: 0009-4374 *
See also references of WO2023173196A1 *
TROXLER F ET AL: "Abwandlungsprodukte von Psilocybin und Psilocin", HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA, HOBOKEN, USA, vol. 42, no. 6, 1 January 1959 (1959-01-01), pages 2073 - 2103, XP002082906, ISSN: 0018-019X, DOI: 10.1002/HLCA.19590420638 *

Also Published As

Publication number Publication date
US20250197351A1 (en) 2025-06-19
AU2022446955A1 (en) 2024-11-07
EP4493541A1 (de) 2025-01-22
CA3246245A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EP4467653C0 (de) Verbesserte mrna-beladene lipidnanopartikel und verfahren zu ihrer herstellung
EP3657150C0 (de) Windkanäle mit prüfabschnitten und verfahren zu ihrer verwendung
EP4037715A4 (de) Proteinmakromolekülkonjugate und verfahren zu ihrer verwendung
EP4150240C0 (de) Schlauchanordnung und verfahren zu ihrer herstellung und verwendung
EP3987021A4 (de) Optimierte proteinlinker und verfahren zu ihrer verwendung
EP4373487A4 (de) Coronavirus-hauptproteasehemmer und verfahren zu ihrer verwendung
EP4486356A4 (de) Polyglutaminsäurezusammensetzungen und verfahren zu ihrer verwendung
EP4430237C0 (de) Nähmaschine und verfahren zu ihrer verwendung
EP3972647A4 (de) Wirkstoffkonjugate und verfahren zu ihrer verwendung
EP4507766A4 (de) Einwegkontrollen, wiederverwendbare vorrichtungen und verfahren zu ihrer verwendung
EP4200329A4 (de) Coronavirus-nanokörper und verfahren zu ihrer verwendung und identifizierung
EP4217982C0 (de) In der höhe angebrachtes sicherheitssystem und verfahren zu dessen verwendung
EP4452962A4 (de) Substituierte benzothiophenderivate und verfahren zu ihrer verwendung
EP4466293A4 (de) Gegen cd47/pd-l1 gerichteter proteinkomplex und verfahren zur verwendung davon
EP3999549A4 (de) Sialidase-pd-l1-antikörperfusionsproteine und verfahren zu ihrer verwendung
EP3911751C0 (de) Leberspezifische induzierbare promotoren und verfahren zu ihrer verwendung
EP4223714C0 (de) Sensibilisierungslösung und verfahren zu ihrer herstellung
EP4266504C0 (de) Anschlussanordnung und verfahren zu ihrer herstellung
EP4493541A4 (de) C4-carbonsäure-substituierte tryptaminderivate und verfahren zu ihrer verwendung
EP4496831A4 (de) Polyhydroxyurethane und verfahren zu ihrer herstellung und verwendung
EP4062912C0 (de) Halbhydrierter utidelon-einkristall und verfahren zu seiner herstellung und seine verwendung
EP4476325A4 (de) Lanthipeptide und verfahren zu ihrer verwendung
EP4536218A4 (de) Siebengliedrige ringverbindungen und verfahren zu deren verwendung
EP4084730A4 (de) Kalibrator für laparoskopisches chirurgiesystem und verfahren zu seiner verwendung
EP4038177A4 (de) Bildgebungssystem und verfahren zu dessen verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260128

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/16 20060101AFI20260122BHEP

Ipc: C07D 401/12 20060101ALI20260122BHEP

Ipc: C07D 405/12 20060101ALI20260122BHEP

Ipc: A61K 31/4045 20060101ALI20260122BHEP

Ipc: A61K 31/4439 20060101ALI20260122BHEP

Ipc: A61P 25/00 20060101ALI20260122BHEP